Pursuant to Regulation 30 read with para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, GlaxoSmithKline Pharmaceuticals has informed that an analyst meeting is scheduled on 9th February 2026.
The above information is a part of company’s filings submitted to BSE.